Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
1999-12-06
2001-06-05
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C264S004100, C264S004300, C264S004600
Reexamination Certificate
active
06241999
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to liposomal formulations of compounds such as drugs. More particularly this invention relates to methods of increasing the encapsulation of desired compounds in liposomal formulations and the methods of making them.
When phospholipids and many other amphipathic lipids are dispersed gently in an aqueous medium they swell, hydrate and spontaneously form multilamellar concentric bilayer vesicles with layers of aqueous media separating the lipid bilayers. These systems commonly are referred to as multilamellar liposomes or multilamellar vesicles (MLV) and usually have diameters of from 0.2 &mgr;m to 5 &mgr;m. Sonication of MLV results in the formation of small unilamellar vesicles (SUV) with diameters usually in the range of 20 to 100 nm, containing an aqueous solution in the core. Multivesicular liposomes (MVL) differ from multilamellar liposomes in the random, non-concentric arrangement of chambers within the liposome. Amphipathic lipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water, but at low ratios the liposome is the preferred structure.
The physical characteristics of liposomes generally depend on PH and ionic strength. They characteristically show low permeability to ionic and polar substances, but at certain temperatures can undergo a gel-liquid crystalline phase (or main phase) transition dependent upon the physical properties of the lipids used in their manufacture which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the liquid crystalline state.
Various types of lipids differing in chain length, saturation, and head group have been used in liposomal drug formulations for years, including the unilamellar, multilamellar, and multivesicular liposomes mentioned above. One of the major goals of the field is to develop liposomal formulations for sustained release of drugs and other compounds of interest, and liposomal formulations from which the rate of release of the encapsulated compound can be controlled.
These goals are important and many studies have been undertaken towards achieving them. Another less recognized goal, increasing the yield of product from a liposomal formulation used as a delivery agent, has very practical benefits as well, particularly to the pharmaceutical industry. For instance, increasing the percent of drug encapsulated in liposomal formulations can result in increased yield and substantial cost savings. In the case of liposomal drug formulations, it is also desirable to have the highest possible percent of drug encapsulated for any given lipid:drug ratio to avoid the need for injecting highly viscous formulations or large volumes into the patient in order to achieve a desired dosage. If a process results in a high percentage of compound encapsulated but yields a product with a low drug:lipid ratio, it is generally necessary that the formulation have a high lipocrit (analogous to hematocrit) in order to satisfy a specified drug dose, or provide a therapeutically effective amount of a biologically active substance via an injection. Analogous to hematocrit, lipocrit is a measure of the percent volume occupied by the liposomes relative to the total volume of the liposome suspension. Yet, such formulations are difficult to administer by injection because of their high viscosities. Thus, the need exists for more and better methods for obtaining liposomal formulations that maximize the efficiency of a drug encapsulation to achieve a low lipid:drug ratio.
SUMMARY OF THE INVENTION
A method is provided for increasing the percent of a compound, such as a drug, that is encapsulated in a liposomal formulation comprising increasing the number of carbons in the carbon chain of at least one lipid in the lipid component of the liposome, wherein the chemical structures of the two lipids are otherwise substantially similar. The preferred length of carbon chain in at least one lipid in a multivesicular liposome is increased to an integer in the range from about 13 to about 28, most preferably about 13 to 22. The preferred lipids of increased carbon chain length are phospholipids.
REFERENCES:
patent: 4078052 (1978-03-01), Papahadjopoulos
patent: 4089801 (1978-05-01), Schneider
patent: 4145410 (1979-03-01), Sears
patent: 4224179 (1980-09-01), Schneider
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4310506 (1982-01-01), Baldeschwieler et al.
patent: 4394372 (1983-07-01), Taylor
patent: 4522803 (1985-06-01), Lenk et al.
patent: 4588578 (1986-05-01), Fountain et al.
patent: 4599227 (1986-07-01), Dees et al.
patent: 4610868 (1986-09-01), Fountain et al.
patent: 4752425 (1988-06-01), Martin et al.
patent: 4769250 (1988-09-01), Forssen
patent: 4781871 (1988-11-01), West, III et al.
patent: 4877619 (1989-10-01), Richer
patent: 4920016 (1990-04-01), Allen et al.
patent: 5000959 (1991-03-01), Tga et al.
patent: 5021200 (1991-06-01), Vanlerberghe et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5204112 (1993-04-01), Hope et al.
patent: 5211955 (1993-05-01), Legros et al.
patent: 5422120 (1995-06-01), Kim
patent: 5723147 (1998-03-01), Kim et al.
patent: 5766627 (1998-06-01), Sankaram et al.
patent: 2050287 (1981-01-01), None
Chapman, D., “Physicochemical Properties of Phospholipids and Lipid-Water Systems”, Liposome Technology, Edited by Gregoriadis, G. CRC Press, 1984, vol. 1, pp. 1-19.
Chapman in Liposome Technology. vol. 1, pp. 1-19 CRC Press. Ed. by Gregoriadis G., 1984.*
Studies on Phosphatidylcholine Vesicles Formation and Physical Characteristics Huang,Biochemistry, 8:334-352, 1969.
Diffusion of Univalent Ions Across The Lamellae of Swollen Phospholipids Bangham,J. Mol. Bio., 13:238-252, 1965.
Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes) Szoka, et al.,Ann. Rev. Biophys. Bioengineering, 2:467-508, 1980.
Evaluation of Retinal Toxicity and Liposome Encapsulation of the Anti-CMV Drug 2′-nor-cyclic GMP Shakiba, et al., Investigative Ophthalmology and Visual Science, No. 10, 34:2903-2910, Sep. 1993.
Fibrin-Enmeshed Tobramycin Liposomes: Single Application Topical Therapy of . . . Frucht-Perry, et al., Cornea, No. 5, 11:393-397, Sep., 1992.
Tobramycin Liposomes. Single Subconjunctival Therapy of . . . Assil, et al.,Investigative Ophthalmology and Visual Science, No. 13, 32:3216-3220, Dec., 1991.
Liposome Suppression of Proliferative Vitreoretinopathy. Rabbit . . . Assil, et al.,Investigative Ophthalmology and Visual Science, No. 11, 32:2891-2897, Oct., 1991.
Magnetic Resonance Imaging of Rabbit Brain After Intracarotid Injection . . . Turski, et al.,Magnetic Resonance in Medicine, No. 2, 7:184-196, Jun., 1988.
Filtering Surgery in Owl Monkeys Treated With the Antimetabolite . . . Skuta, et al.,American Journal of Ophthalmology, No. 5, 103:714-716, May 15, 1987.
Multivesicular Liposomes. Sustained Release of the Antimetabolite . . . Assil, et al.,Archives of Ophthalmology, No. 3, 105:400-403, Mar. 1987.
Weak Acid-Induced Release of Liposome-Encapsulated Carboxyfluorescein Barbet, et al.,Biochimica et Biophysica Acta, No. 3, 772:347-356, May 30, 1984.
Preparation of Cell-Size Unilamellar Liposomes with High Captured Volume and Defined Size . . . Kim, et al.,Biochim. Biophys. Acta, 646:1-9, 1981.
Preparation of Multivesicular Liposomes Kim, et al.,Biochim. Biophys. Acta, 728:339-348, 1983.
Preparation of Multilamellar Vesicles of Defined Size-Distribution by Solvent-Spherule . . . Kim, et al.,Biochim. Biophys. Acta, 812:793-801, 1985.
Multivesicular Liposomes Containing Cytarabine Entrapped in the Presence of . . . Kim, et al.,Cancer Treat. Rep., 71:705-711, 1987.
Multivesicular Liposomes Containing Cytosine 1-&bgr;-D-Arabinofuranosylcytosine for Slow-Release Intrathecal Therapy Kim, et al.,Cancer Research, 47:3935-3937, 1987.
Multivesicular Liposomes Containing Cytosine for Slow Release . . . Kim, et al.,Cancer Treat Rep., 71:447-450, 1987.
Sankaram Mantripragada Bhima
Ye Qiang
Fish & Richardson P.C.
Kishore Gollamudi S.
SkyePharma Inc.
LandOfFree
Method for producing liposomes with increased percent of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing liposomes with increased percent of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing liposomes with increased percent of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2489082